Literature DB >> 17922976

Relief from sleep apnea after radiation and chemotherapy.

Ahmet Ursavaş1, Mehmet Karadag, Basak Burgazlioglu, Funda Coşkun, Esma Ceylan, Selçuk Onart, R Oktay Gozu.   

Abstract

Superior vena cava syndrome (SVCS) can result from extrinsic compression by a primary tumor, mediastinal lymph nodes metastases, benign lesions, or intraluminal thrombosis. The association between obstructive sleep apnea and SVCS has not been extensively evaluated. To our knowledge, only 5 cases of obstructive sleep apnea in SVCS have been reported in the literature. We presented a 53-year-old man who was admitted with dyspnea, edema of the face, and excessive daytime sleepiness. Chest radiography and computed tomography revealed lung cancer. A biopsy of the tumor revealed squamous cell carcinoma. Obstructive sleep apnea was diagnosed by polysomnography (apnea hypopnea index: 13 per hour). After radiation and chemotherapy, edema of the face, snoring, and daytime sleepiness were alleviated, and the patient's apnea hypopnea index decreased to 0.6 per hour. In conclusion, there is a relationship between obstructive sleep apnea and SVCS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922976     DOI: 10.3816/CLC.2007.n.036

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  3 in total

1.  Complications of central venous stenosis due to permanent central venous catheters in children on hemodialysis.

Authors:  Choni Rinat; Efrat Ben-Shalom; Rachel Becker-Cohen; Sofia Feinstein; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2014-08-22       Impact factor: 3.714

2.  Worsening of Obstructive Sleep Apnea Associated with Catheter-Related Superior Vena Cava Syndrome.

Authors:  Marie Jouvenot; Serge Willoteaux; Nicole Meslier; Frédéric Gagnadoux
Journal:  J Clin Sleep Med       Date:  2015-06-15       Impact factor: 4.062

Review 3.  Sleep and cancer: recent developments.

Authors:  Michael J Sateia; Bianca J Lang
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.